Ryan Allway July 7th, 2021 Psychedelics TORONTO, July 07, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and neuropsychiatric disorders with unmet medical needs, today announced... Read more
Lobe Sciences Enters into LOI with Core One Labs to Form a Joint Venture for the Clinical Development of Biosynthetic Psilocybin
April 29, 2021
Ryan Allway April 29th, 2021 Psychedelics Vancouver, British Columbia–(Newsfile Corp. – April 28, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to announce it has entered into a non-binding letter of intent dated April 27, 2021 (the “Agreement“) with Core One... Read more
Core One Labs to Explore Joint Venture with Lobe Sciences for the Clinical Development of Biosynthetic Psilocybin
April 28, 2021
Ryan Allway April 28th, 2021 Psychedelics VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“Core One”) is pleased to announce it has entered into a letter of intent, dated April 27, 2021, with Lobe Sciences Ltd. (“Lobe”) pursuant... Read more
